Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Citalopram During TMS in MDD
NCT04846829Phase 1Active, not recruiting
- Sponsor
- University of California, Los Angeles
- Start
- Apr 2017
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of citalopram in major depressive disorder (MDD) (4 arms), sponsored by University of California, Los Angeles. Primary endpoint: Hamilton Depression Rating Scale at 10 days. Started Apr 2017; status: active, not recruiting.
02
Drugs
citalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04846829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04846829.